Array BioPharma Inc. girma, binimetinib, Braftova, encorafenib, Mektovi, Pfizer
Encorafenib tare da binimetinib an amince da ita ta FDA don maganin ciwon huhu mara ƙananan ƙwayar cuta tare da maye gurbin BRAF V600E.
Hukumar Abinci da Magunguna (FDA) ta amince da Encorafenib (Braftovi, Array BioPharma Inc., reshen mallakar Pfizer gaba ɗaya) da binimetinib (Mektovi, Array BioPharma Inc.) a cikin Nuwamba 2023 a matsayin magunguna waɗanda za a iya amfani da su don…
Bosulif, Bosutinib, cutar sankarar bargo mai tsafta, CML, Pfizer
FDA ta amince da Bosutinib don marasa lafiya na yara masu fama da cutar sankarar bargo na myelogenous
Nov 2023: Ga marasa lafiya na yara masu shekaru shekara ɗaya zuwa sama tare da lokaci na yau da kullun (CP) Ph+ cutar sankarar jini na myelogenous (CML), ko dai sabon bincike (ND) ko juriya ko rashin haƙuri (R/I) zuwa maganin baya, Abinci da Drug Admini. .
Pfizer, TALAPRO-2, Talazoparib
Talazoparib tare da enzalutamide an amince da shi ta FDA don HRR-mutated metastatic castration-resistant prostate cancer
Yuli 2023: Hukumar Abinci da Magunguna ta share talazoparib (Talzenna, Pfizer, Inc.) tare da enzalutamide don gyaran haɗe-haɗe (HRR) maye gurbi a cikin ciwon gurguwar ƙwayar cuta mai jurewa (mCRPC). TALAP..
Saukewa: ADVL0912, anaplastic lymphoma kinase, linzoma, NCT00939770, Pfizer, Xalkori
Crizotinib an amince da shi ta FDA don ALK-tabbatacce mai kumburi myofibroblastic tumor
Yuli 2022: Crizotinib (Xalkori, Pfizer Inc.) ya sami izini daga Hukumar Abinci da Magunguna (FDA) don kula da manya da marasa lafiya na yara masu shekaru 1 da haihuwa waɗanda aka gano da rashin lafiya, maimaituwa.
ALK, B7461006, crizotinib, Lorbrena, lolatinib, NCT03052608, Pfizer, Ventana ALK, Tsarin Kiwon Lafiya na Ventana
FDA ta amince da Lorlatinib don kula da metastatic ALK-positive NSCLC.
Agusta 2021: Lorlatinib (Lorbrena, Pfizer Inc.) ya karɓi amincewar FDA ta yau da kullun ga marasa lafiya da ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (NSCLC) wanda ciwace-yawacen ta su ne anaplastic lymphoma kinase (ALK)-tabbatacce, kamar yadda FDA-app ta ƙaddara.
anaplastic lymphoma kinase, B7461006, CDx Assay, Abinci da Drug Administration, Lorbrena, lolatinib, NCT03052608, Bayanin NSCLC, Pfizer, Ventana ALK, Tsarin Kiwon Lafiya na Ventana
FDA ta amince da Lorlatinib don kula da metastatic ALK-positive NSCLC
Agusta 2021: Lorlatinib (Lorbrena, Pfizer Inc.) ya karɓi amincewar FDA ta yau da kullun ga marasa lafiya da ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (NSCLC) wanda ciwace-yawacen ta su ne anaplastic lymphoma kinase (ALK)-tabbatacce, kamar yadda FDA-app ta ƙaddara.
Bharat Biotech, Coronavirus, covaxin, Covid, Maganin rigakafin covid, Covichield, Pfizer
COVID-19 Alurar riga kafi - Duk abin da kuke son sani
Dokta Julie Gralow ta amsa tambayoyi kan rigakafin COVID-19. Ta yaya za mu tabbata cewa alluran ba su da lafiya idan an samar da su kuma an amince da su cikin kankanin lokaci?